Massachusetts-based Amylyx Pharmaceuticals, Inc. conducted a clinical trial evaluating AMX0035, an investigational neuroprotective therapy designed to reduce the death and dysfunction of motor neurons in people suffering from ALS. The trial was shown to slow the progression of ALS. Top Featured Tags: – Ohio News Press Release Distribution Service
Search TopFeatured.com
Top Featured Tag Cloud
- Alabama News
- Alaska News
- Arizona News
- Arkansas News
- Business
- California News
- Colorado News
- Connecticut News
- Coronavirus
- Delaware News
- DIY
- Flights
- Florida News
- Food
- Georgia News
- Hawaii News
- History
- Idaho News
- Illinois News
- Indiana News
- Iowa News
- Kansas News
- Kentucky News
- Louisiana News
- Maryland News
- Massachusetts News
- Michigan News
- Minnesota News
- Mississippi News
- Missouri News
- Montana News
- Nebraska News
- Nevada News
- New Hampshire News
- New Jersey News
- New Mexico News
- New York News
- North Carolina News
- North Dakota News
- Ohio News
- Oregon News
- Philadelphia News
- Politics
- Protests
- Rhode Island News
- Rioting
- South Dakota News
- Tennessee News
- Texas News
- Travel
- Utah News
- Vermont News
- Virginia News
- Washington DC News
- Washington News
- West Virginia News
- Wisconsin News
- World News
- Wyoming News
Crypto Currency